Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Abeona Therapeutics Announces $35 Million Private Placement Financing
-
Abeona Therapeutics Announces $35 Million Private Placement Financing
-
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
-
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
-
Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
Abeona Therapeutics (ABEO) Prices 44.7M Stock and Warrant Offering at $0.39/sh
-
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
-
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
-
Abeona Therapeutics (ABEO) to Offer Common Stock and Warrants
-
Abeona Therapeutics Announces Public Offering of Common Stock and Warrants
-
Abeona Therapeutics Announces Public Offering of Common Stock and Warrants
-
Abeona Therapeutics to Present at Upcoming Investor Conferences
-
Abeona Therapeutics to Present at Upcoming Investor Conferences
-
Pre-Open Stock Movers 11/11: (FPRX) (FUBO) (SURF) Higher; (EGAN) (ACB) (MODN) Lower (more...)
-
After-Hours Movers 11/10: (FPRX) (FUBO) (BRKS) Higher; (EGAN) (MODN) (LYFT) Lower (more...)
-
Abeona Therapeutics (ABEO) Seen 'Aggressively' Pursuing a Sale Following Board and CEO Departures - Cantor Fitzgerald
-
Pre-Open Stock Movers 2/10: (VTVT) (EPC) (TSLA) Higher (ABUS) (BHVN) (LLY) Lower (more...)
-
Cantor Fitzgerald Downgrades Abeona Therapeutics (ABEO) to Neutral
-
Abeona Therapeutics (ABEO) PT Lowered to $29 at Cantor Fitzgerald; Maintains Buy
-
Abeona Announces Participation at Upcoming Conferences
-
Abeona Announces Participation at Upcoming Conferences
-
Abeona Therapeutics (ABEO) PT Raised to $36 at Cantor Fitzgerald
-
Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Abeona Therapeutics (ABEO) Prices 5M Share Common Offering at $16/Sh
-
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock
-
Abeona Therapeutics (ABEO) PT Raised to $34 at Cantor Fitzgerald
-
Abeona Therapeutics Announces Upcoming Conference Participation
-
Cantor Fitzgerald Reiterates Overweight Rating and $21 PT on Abeona Therapeutics (ABEO); Positive ABO-102 Data
-
Abeona Therapeutics (ABEO) Defended at Cantor Fitzgerald Following 'Factually Incorrect and Misleading' Article
-
Abeona Therapeutics Inc. Announces Closing of its Underwritten Offering of Common Stock
-
Abeona Therapeutics (ABEO) Prices 6M Shares at $7/Share
-
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock
-
Abeona Therapeutics (ABEO) ABO-102 Data is a 'Promising Start' - Cantor Fitzgerald
-
Pre-Open Stock Movers 09/08: (RPRX) (RAD) (JUNO) Higher; (GEVO) (NLST) (TSCO) (PIR) Lower (more...)
-
After-Hours Stock Movers 09/07: (RPRX) (JUNO) (ABEO) Higher; (GEVO) (TSCO) (PIR) Lower (more...)
-
Cantor Fitzgerald Starts Abeona Therapeutics (ABEO) at Buy, $21 PT
-
Abeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

